We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

MXCT Maxcyte Inc

3.00 (0.91%)
24 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  3.00 0.91% 333.00 5,137 08:00:00
Bid Price Offer Price High Price Low Price Open Price
326.00 340.00 333.00 333.00 333.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics USD 41.29M USD -37.92M USD -0.3664 -11.41 432.65M
Last Trade Time Trade Type Trade Size Trade Price Currency
15:26:37 O 4,500 335.10 GBX

Maxcyte (MXCT) Latest News

Maxcyte (MXCT) Discussions and Chat

Maxcyte Forums and Chat

Date Time Title Posts
11/6/202414:48Maxcyte: Any molecule, any cell, any scale1,496
21/1/202214:00Anybody know what is going on?-
13/7/202112:48MaxCyte (MXCT) Right here, right now: catching the CAR-T wave5

Add a New Thread

Maxcyte (MXCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-06-24 14:26:38335.104,50015,079.50O
2024-06-24 12:28:54338.002,5008,450.00O
2024-06-24 12:28:51338.002,5008,450.00O
2024-06-24 12:07:30327.2513.27O
2024-06-24 11:08:18327.506362,082.90O

Maxcyte (MXCT) Top Chat Posts

Top Posts
Posted at 24/6/2024 09:20 by Maxcyte Daily Update
Maxcyte Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker MXCT. The last closing price for Maxcyte was 330p.
Maxcyte currently has 103,504,571 shares in issue. The market capitalisation of Maxcyte is £432,649,107.
Maxcyte has a price to earnings ratio (PE ratio) of -11.41.
This morning MXCT shares opened at 333p
Posted at 05/3/2024 08:59 by adamb1978
Not sure Dave. THe core revenue growth figure is underwhelming - new licenses are meant to tranlsate into incremental revenues...wonder whether:

- any licensees have terminated?
- any have asked for restructured/written off payments due to funding problems?
- MXCT have changed commercial structures?
Posted at 30/1/2024 16:38 by mysteronz
These SPL signings are really starting to grow now.

Maybe a sign of increased confidence in bio investment or the MXCT platform, either way future money in the bank/sign on fee :)
Posted at 08/12/2023 18:32 by adamb1978
Very nice. Share price down 4% in NY!!
Posted at 08/12/2023 17:36 by lancasterbomber
Surprised share price went down not up
Posted at 01/11/2023 09:20 by 74tom
Some interesting comments on this old seeking alpha article;

"Another important point on the competitive position is the potential long-term customer lock-in that MXCT can achieve, on top of the long-term partnership agreements. If a therapy gets FDA approval using MXCT's tech, that would be considered a critical supplier, I expect it will be very difficult to switch after approval (long and uncertain validation process to prove bio-equivalence, etc).
However, you don't mention anything on MXCT's IP. Is their technology well protected and what's the remaining life of their patents?"

"I agree that there is no sense in switching to another service provider once a therapy is FDA approved using MaxCyte's technology. In terms of IP there is quite a lot of information in the Prospectus. I will just copy an extract here: "As of May 4, 2021, we have 50 granted U.S. and foreign patents, including in foreign 109 jurisdictions such as Australia, Canada, Japan, China, South Korea and certain countries in Europe, as well as 76 pending patent applications worldwide. The main focus of our patent coverage protects our Flow Electroporation, processing chambers/disposables, control and process elements, and methods of using our non-viral delivery platform. Our patent portfolio provides protection over our instruments and related methods through at least 2028 and over our electroporation applications and methods through 2034. We are also working to secure design protection of the ExPERT system, which has the potential to provide protection through at least 2036."

That's very impressive on the patent front...
Posted at 27/9/2023 18:32 by adamb1978
Whether luck or judgement, MXCT timed their Nasdaq listing to perfection. Without that, they'd have gone under. However they now have a decade of cash runway.

If the Cripsr thing gets approval at the end of Nov, this share price should rocket
Posted at 27/9/2023 13:39 by adamb1978
Cash isn’t remotely an issue here. As the other poster said, they have boat loads of the stuff!

Question is whether their lead customer gets approval back from the regulators in a couple months time

The share price at the moment is effectively assuming that gets rejected. You can understand the price drifting down over recent months as such a big proportion of the newsflow for MXCT this year is the end-nov approval.

Therefore there’s big upside of the green light comes. If it doesn’t, I wouldn’t be surprised if the Board looks for a buyer and a huge MedTech type company sweeps them up
Posted at 23/9/2023 13:01 by adamb1978

Difficult with an offer would be valuation. Is that a price which (i) the Directors would recommend and (ii) someone would offer

As you say, the business is almost free (net of cash) so the premium would need to be huge, and could an acquiror get that through their board?

MXCT share price is really in a holding pattern until the regulatory approval is back on Crispr...not long to go now though!

Posted at 23/9/2023 08:04 by 74tom
Looking interesting here from a valuation standpoint given the upcoming catalysts.

At the start of Covid MXCT raised capital at £1.31, post that raise they had ~£35m cash & 76.5m shares in issue, giving a post raise cap of £100m & EV of £65m / $80m.

At last nights $3.12 close on NASDAQ the market cap was down to $336m with cash likely to be ~$210m ($5m quarterly burn net of interest income). So EV of $126m.

Therefore, if EV declines by another $46m, the company is as fundamentally cheap as at the start of Covid, but with 4x as much cash. Share price wise that equates to around $2.80 / £2.30.

Giving the world class IP & industry standing, surely there is a real risk of a takeover attempt?
Posted at 15/3/2023 09:33 by adamb1978
Results are this evening, though we already know the 2022 top line figure and their initial guidance for 2023.

MXCT share price has been weak recently however if you look at various other healthcare companies, most of them have come off too.
Maxcyte share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock